MCID: CND002
MIFTS: 54

Conduct Disorder

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to impulse control disorder and oppositional defiant disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 32.7 DRD2 DRD4
2 oppositional defiant disorder 31.3 COMT DBH DRD2 DRD4 MAOA SLC6A3
3 anxiety 29.8 COMT MAOA SLC6A3 SLC6A4 TPH1
4 alcohol use disorder 29.8 ALDH2 DRD2 SLC6A4
5 borderline personality disorder 29.6 COMT MAOA SLC6A4 TPH1
6 alcohol abuse 29.6 ALDH2 DRD2 DRD4 SLC6A4
7 antisocial personality disorder 29.6 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
8 substance dependence 29.3 DRD2 DRD4 DRD5 MAOA SLC6A3 SLC6A4
9 tic disorder 29.2 DRD2 DRD4 DRD5 SLC6A3
10 autism 29.0 COMT DRD2 DRD4 MAOA OXTR RBFOX1
11 personality disorder 28.9 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
12 substance abuse 28.7 COMT DBH DRD2 DRD4 DRD5 MAOA
13 autism spectrum disorder 28.5 COMT DRD2 DRD4 MAOA OXTR RBFOX1
14 attention deficit-hyperactivity disorder 28.4 COMT DBH DRD2 DRD4 DRD5 MAOA
15 tobacco addiction 28.4 ALDH2 COMT DRD2 MAOA SLC6A3 TPH1
16 panic disorder 28.4 ADORA2A COMT MAOA SLC6A4 TPH1
17 major depressive disorder 28.3 COMT DRD2 DRD4 MAOA OXTR SLC6A3
18 disease of mental health 28.2 ALDH2 COMT DRD2 DRD4 MAOA OXTR
19 alcohol dependence 27.6 ALDH2 COMT DBH DRD2 DRD4 GRIN1
20 bipolar disorder 27.6 COMT DBH DRD2 DRD4 DRD5 GRIN1
21 schizophrenia 26.6 ADORA2A COMT DBH DRD2 DRD4 DRD5
22 cardiomyopathy, dilated, 1e 11.1
23 heart conduction disease 11.0
24 familial progressive cardiac conduction defect 11.0
25 wolff-parkinson-white syndrome 10.9
26 progressive familial heart block, type ia 10.9
27 cardiac conduction defect 10.9
28 atypical depressive disorder 10.4 MAOA SLC6A4
29 delusional disorder 10.4 DRD2 DRD4
30 phobia, specific 10.4 COMT MAOA
31 schizophreniform disorder 10.4 COMT DRD2
32 polysubstance abuse 10.4 COMT DRD2
33 tardive dyskinesia 10.3 COMT DRD2
34 alcohol-induced mental disorder 10.3 DRD2 SLC6A3 SLC6A4
35 premature ejaculation 10.3 COMT SLC6A3 SLC6A4
36 alcoholic psychosis 10.3 DRD2 SLC6A3 SLC6A4
37 heroin dependence 10.3 DRD2 DRD4 SLC6A3
38 dependent personality disorder 10.3 DRD4 MAOA
39 migraine without aura 10.3 DRD2 DRD4 SLC6A4
40 phobic disorder 10.3 COMT MAOA SLC6A4
41 social phobia 10.3 DRD2 MAOA SLC6A4
42 dysthymic disorder 10.3 MAOA SLC6A4
43 paranoid schizophrenia 10.3 COMT MAOA SLC6A4
44 childhood-onset schizophrenia 10.3 COMT TPH1
45 separation anxiety disorder 10.3 DRD4 OXTR SLC6A3
46 bulimia nervosa 1 10.2 COMT MAOA SLC6A4
47 striatonigral degeneration 10.2 DRD2 SLC6A3
48 schizoaffective disorder 10.2 COMT DRD2 SLC6A4
49 chronic fatigue syndrome 10.2 COMT MAOA SLC6A4
50 stuttering 10.2 DBH DRD2 SLC6A3

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

MGI Mouse Phenotypes related to Conduct Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ADORA2A DRD2 ALDH2 DRD4 DRD5 CAMK2A
2 homeostasis/metabolism MP:0005376 10.07 ADORA2A DRD2 ALDH2 DRD4 CAMK2A COMT
3 cardiovascular system MP:0005385 10.06 ADORA2A DRD2 DRD5 COMT GRIN1 DBH
4 growth/size/body region MP:0005378 10.02 DBH ADORA2A DRD2 ALDH2 GRIN1 TPH1
5 endocrine/exocrine gland MP:0005379 9.97 DRD2 ALDH2 DRD5 COMT DBH OXTR
6 integument MP:0010771 9.81 ADORA2A DRD2 ALDH2 CAMK2A DBH TPH1
7 nervous system MP:0003631 9.8 ADORA2A DRD2 ALDH2 DRD4 DRD5 CAMK2A
8 normal MP:0002873 9.17 DBH DRD2 DRD5 GRIN1 OXTR SLC6A3

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 20748-11-2, 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Carbidopa Approved Phase 4 28860-95-9 38101 34359
5
Levodopa Approved Phase 4 59-92-7 6047
6
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
7
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
8
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
9
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
10
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
11
Oxcarbazepine Approved Phase 4 28721-07-5 34312
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
14
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
15
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
16
Citalopram Approved Phase 4 59729-33-8 2771
17
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
18
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
19
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
20
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
21
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
22
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
23
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
24
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
25 Antipsychotic Agents Phase 4,Phase 3,Phase 2
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
27 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Dopamine Antagonists Phase 4,Phase 3,Phase 2
30 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2
34
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
35 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Serotonin Antagonists Phase 4,Phase 3,Phase 2
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2
38 Antiparkinson Agents Phase 4,Phase 2
39 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
40 Autonomic Agents Phase 4,Phase 3,Phase 2
41 Dopamine agonists Phase 4,Phase 3,Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anticonvulsants Phase 4,Phase 2
45 Antimanic Agents Phase 4,Phase 3
46 GABA Agents Phase 4
47 Anti-Obesity Agents Phase 4,Phase 2
48 Neuroprotective Agents Phase 4,Phase 2
49 Analgesics Phase 4,Phase 2
50 Analgesics, Non-Narcotic Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 215)

# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg)
3 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
4 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
5 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
6 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. Completed NCT00154362 Phase 4 Oxcarbazepine
7 Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
8 Early Prevention of Conduct Problems Completed NCT00051714 Phase 4
9 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
10 Treatment of Severe Childhood Aggression (The TOSCA Study) Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
11 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
12 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
13 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
14 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
15 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
16 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
17 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
18 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
19 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
20 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
21 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
22 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
23 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
24 Multidimensional Treatment Foster Care for Adolescents Withdrawn NCT01726361 Phase 4
25 Long-Term Lithium Treatment for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
26 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
27 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
28 Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
29 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
30 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3
31 Personality-targeted Interventions for Adolescent Alcohol Misuse Completed NCT00344474 Phase 2, Phase 3
32 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
33 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
34 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
35 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
36 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
37 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
38 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
39 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Not yet recruiting NCT03146130 Phase 3
40 How the Adolescent Inpatients Are Rehabilitated After Discharge Terminated NCT01709526 Phase 2, Phase 3
41 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 LY2216684
42 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
43 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
44 Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling Unknown status NCT01529047 Phase 2
45 Prevention of School Dropout for Mexican American Adolescents Completed NCT00051727 Phase 2
46 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
47 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
48 Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Completed NCT00626236 Phase 2 SPN-810;SPN-810;SPN-810;SPN-810
49 Randomized Control Trial of Group Intervention With Former War-affected Boys in the Democratic Republic of Congo Completed NCT01494831 Phase 2
50 Memantine in the Treatment of Kleptomania Completed NCT00880685 Phase 2 Memantine

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

38
Brain, Testes, Skin, Amygdala, Cortex, Eye, Temporal Lobe

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 665)
# Title Authors Year
1
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
2
Social skills training and play group intervention for children with oppositional-defiant disorders/conduct disorder: Mediating mechanisms in a head-to-head comparison. ( 29347904 )
2018
3
Anatomy of the dorsal default-mode network in conduct disorder: Association with callous-unemotional traits. ( 29413533 )
2018
4
Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder. ( 29324397 )
2018
5
Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder. ( 29348532 )
2018
6
Hiccup Due to Aripiprazole Plus Methylphenidate Treatment in an Adolescent with Attention Deficit and Hyperactivity Disorder and Conduct Disorder: A Case Report. ( 29073754 )
2017
7
The reliability, concurrent validity and association with salivary oxytocin of the self-report version of the Inventory of Callous-Unemotional Traits in adolescents with conduct disorder. ( 28628793 )
2017
8
Implicit Attitudes Toward Violence in a Sample of Adolescent Offenders With Conduct Disorder. ( 29294969 )
2017
9
Sex Differences in the Relationship Between Conduct Disorder and Cortical Structure inA Adolescents. ( 28735700 )
2017
10
Short- and long-range functional connectivity density alterations in adolescents with pure conduct disorder at resting-state. ( 28377176 )
2017
11
Facial emotion recognition and eye movement behaviour in conduct disorder. ( 28881001 )
2017
12
Body Mass Index z-Scores and Weight Status Predict Conduct Disorder Symptoms in Adolescents. ( 28867351 )
2017
13
Community Violence Exposure and Conduct Problems in Children and Adolescents with Conduct Disorder and Healthy Controls. ( 29163090 )
2017
14
Comorbidities and correlates of conduct disorder among male juvenile detainees in South Korea. ( 28924450 )
2017
15
Investigation of the Changes in the Power Distribution in Resting-State Brain Networks Associated with Pure Conduct Disorder. ( 28717223 )
2017
16
Empathic skills and theory of mind in female adolescents with conduct disorder. ( 28614490 )
2017
17
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
18
Disrupted small-world brain network topology in pure conduct disorder. ( 29029449 )
2017
19
A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. ( 29073744 )
2017
20
Conduct Disorder Symptoms and Illicit Drug Use in Juvenile Justice Involved Youth: The Reciprocal Relationship Between Positive Illicit Drug-Use Attitudes and Illicit Drug Use. ( 29185888 )
2017
21
A systematic review on the prevalence of conduct disorder in the Middle East. ( 28681265 )
2017
22
Altered White-Matter Microstructure in Conduct Disorder Is Specifically Associated with Elevated Callous-Unemotional Traits. ( 29273881 )
2017
23
Alterations of Brain Functional Architecture Associated with Psychopathic Traits in Male Adolescents with Conduct Disorder. ( 28900210 )
2017
24
Neurocognitive characteristics of youth with noncomorbid and comorbid forms of conduct disorder and attention deficit hyperactivity disorder. ( 28636895 )
2017
25
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
26
Mental health among young adults in prison: the importance of childhood-onset conduct disorder. ( 28357134 )
2017
27
Associations between a history of traumatic brain injuries and conduct disorder during youth in a population sample of Canadian adults. ( 28867408 )
2017
28
Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence. ( 28695488 )
2017
29
Affect recognition among adolescents in therapeutic schools: relationships with posttraumatic stress disorder and conduct disorder symptoms. ( 28503096 )
2017
30
Sex differences in risk-based decision making in adolescents with conduct disorder. ( 28688012 )
2017
31
Taxometric analyses and predictive accuracy of callous-unemotional traits regarding quality of life and behavior problems in non-conduct disorder diagnoses. ( 28427034 )
2017
32
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
33
Population cost-effectiveness of the Triple P parenting programme for the treatment of conduct disorder: an economic modelling study. ( 29288334 )
2017
34
Conduct Disorder ( 29261891 )
2017
35
Familial early infantile epileptic encephalopathy and cardiac conduction disorder: A rare cause of SUDEP in infancy. ( 28697420 )
2017
36
Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder. ( 28292624 )
2017
37
Transitions and Motivations for Substance Misuse in Prison Inmates With ADHD and Conduct Disorder: Validation of a New Instrument. ( 28418789 )
2017
38
Different brain responses during empathy in autism spectrum disorders versus conduct disorder and callous-unemotional traits. ( 26681358 )
2016
39
Mediating and Moderating Role of Depression, Conduct Disorder or Attention-Deficit/Hyperactivity Disorder in Developing Adolescent Substance Use Disorders: A Population-Based Study. ( 27294778 )
2016
40
Correlates of conduct disorder among inmates of a Nigerian Borstal Institution. ( 27330558 )
2016
41
Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( 27816696 )
2016
42
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
43
Ventral striatum and amygdala activity as convergence sites for early adversity and conduct disorder. ( 27694318 )
2016
44
Empathic Accuracy in Male Adolescents with Conduct Disorder and Higher versus Lower Levels of Callous-Unemotional Traits. ( 28032270 )
2016
45
Emotion Regulation Difficulties in Boys with Oppositional Defiant Disorder/Conduct Disorder and the Relation with Comorbid Autism Traits and Attention Deficit Traits. ( 27420110 )
2016
46
Does comorbid anxiety counteract emotion recognition deficits in conduct disorder? ( 26934047 )
2016
47
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
48
Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder. ( 27574842 )
2016
49
Disrupted Topological Patterns of Large-Scale Network in Conduct Disorder. ( 27841320 )
2016
50
Genetic influences on conduct disorder. ( 27350097 )
2016

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
2 12.45 CAMK2A COMT DBH GRIN1 TPH1
3
Show member pathways
12.43 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
4 12.21 DRD2 DRD4 DRD5 GRIN1
6
Show member pathways
12.1 ADORA2A CAMK2A DRD5 GRIN1 OXTR
7
Show member pathways
12.1 ADORA2A CAMK2A DRD2 DRD5 GRIN1 OXTR
8 12.05 GRIN1 MAOA SLC6A4 TPH1
9
Show member pathways
12.02 CAMK2A DRD2 DRD4 DRD5 GRIN1
10
Show member pathways
11.84 DRD2 DRD4 DRD5
11 11.83 MAOA SLC6A4 TPH1
12
Show member pathways
11.83 CAMK2A DRD2 GRIN1 MAOA SLC6A3
13 11.71 DBH MAOA TPH1
14
Show member pathways
11.62 COMT DBH MAOA
15 11.52 CAMK2A GRIN1 RBFOX1
16 11.13 MAOA SLC6A4 TPH1
17
Show member pathways
10.99 ADORA2A DBH MAOA SLC6A3 SLC6A4
18 10.95 DRD2 DRD5
19
Show member pathways
10.9 COMT DBH MAOA TPH1
20
Show member pathways
10.81 ALDH2 COMT MAOA
21 10.74 COMT MAOA
22
Show member pathways
10.7 ALDH2 MAOA
23
Show member pathways
10.44 ALDH2 COMT MAOA SLC6A3 SLC6A4

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.71 ADORA2A COMT DRD2 GRIN1
2 axon GO:0030424 9.56 ADORA2A COMT DRD2 SLC6A3
3 dendritic spine GO:0043197 9.5 COMT DRD2 GRIN1
4 postsynaptic density GO:0014069 9.46 ADORA2A CAMK2A DRD2 GRIN1
5 non-motile cilium GO:0097730 9.43 DRD2 DRD5
6 neuron projection GO:0043005 9.35 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
7 integral component of plasma membrane GO:0005887 9.23 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
8 plasma membrane GO:0005886 10.16 ADORA2A CAMK2A COMT DRD2 DRD4 DRD5
9 integral component of membrane GO:0016021 10.11 ADORA2A COMT DBH DRD2 DRD4 DRD5

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.87 COMT OXTR SLC6A3
2 response to ethanol GO:0045471 9.86 DRD2 GRIN1 SLC6A3
3 response to drug GO:0042493 9.85 ADORA2A COMT DRD2 OXTR SLC6A3 SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.82 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.81 ADORA2A DBH DRD2 SLC6A3
6 excitatory postsynaptic potential GO:0060079 9.79 ADORA2A DRD2 GRIN1
7 learning GO:0007612 9.77 COMT DRD5 GRIN1
8 memory GO:0007613 9.76 DBH GRIN1 OXTR SLC6A4
9 visual learning GO:0008542 9.74 DBH DRD2 GRIN1
10 eating behavior GO:0042755 9.71 ADORA2A OXTR
11 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD4
12 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD4
13 synaptic transmission, glutamatergic GO:0035249 9.71 ADORA2A GRIN1
14 social behavior GO:0035176 9.71 DRD4 GRIN1 OXTR SLC6A4
15 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
16 regulation of neuronal synaptic plasticity GO:0048168 9.7 CAMK2A GRIN1
17 regulation of long-term neuronal synaptic plasticity GO:0048169 9.7 DRD2 GRIN1
18 response to pain GO:0048265 9.7 COMT DBH
19 dopamine receptor signaling pathway GO:0007212 9.7 DRD2 DRD4 DRD5
20 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.69 ADORA2A OXTR
21 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD4
22 startle response GO:0001964 9.68 DRD2 GRIN1
23 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
24 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.68 DRD2 DRD5
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 DRD4
26 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
27 positive regulation of renal sodium excretion GO:0035815 9.67 ADORA2A DRD2
28 synaptic transmission, dopaminergic GO:0001963 9.67 ADORA2A DRD2 DRD5
29 positive regulation of urine volume GO:0035810 9.66 ADORA2A DRD2
30 suckling behavior GO:0001967 9.66 GRIN1 OXTR
31 positive regulation of synaptic transmission, GABAergic GO:0032230 9.65 ADORA2A OXTR
32 maternal behavior GO:0042711 9.65 DBH OXTR
33 behavioral response to ethanol GO:0048149 9.65 DBH DRD2 DRD4
34 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.64 DRD2 DRD4
35 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOA
36 catecholamine metabolic process GO:0006584 9.63 COMT MAOA
37 regulation of dopamine metabolic process GO:0042053 9.63 DRD4 SLC6A3
38 adenohypophysis development GO:0021984 9.62 DRD2 SLC6A3
39 monoamine transport GO:0015844 9.62 SLC6A3 SLC6A4
40 response to cocaine GO:0042220 9.62 DRD2 DRD5 OXTR SLC6A3
41 inhibitory postsynaptic potential GO:0060080 9.61 ADORA2A DRD4
42 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
43 dopamine uptake involved in synaptic transmission GO:0051583 9.59 SLC6A3 SLC6A4
44 sperm ejaculation GO:0042713 9.58 OXTR SLC6A4
45 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.58 DRD5 OXTR
46 fear response GO:0042596 9.56 DBH DRD4
47 associative learning GO:0008306 9.56 DBH DRD2 DRD5 GRIN1
48 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.55 DRD2 DRD4
49 response to histamine GO:0034776 9.54 DRD2 DRD4
50 prepulse inhibition GO:0060134 9.46 ADORA2A DRD2 GRIN1 SLC6A3

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 ADORA2A DRD2 DRD4 DRD5 OXTR
2 signal transducer activity GO:0004871 9.65 ADORA2A DRD2 DRD4 DRD5 OXTR
3 drug binding GO:0008144 9.58 DRD2 DRD4 SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A3 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A3 SLC6A4
8 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
9 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Conduct Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....